Form 4: Rapport Therapeutics Director Granted Stock Options Valued at $10.95 Per Share

Rapport Therapeutics, Inc. Director Steven M. Paul was granted 21,850 stock options with an exercise price of $10.95 per share, vesting upon specific conditions.

Summary

• Steven M. Paul, a Director of Rapport Therapeutics, Inc. (RAPP), was granted 21,850 stock options.
• The stock options have an exercise price of $10.95 per share.
• The transaction date for this grant was June 17, 2025.
• The options are set to expire on June 17, 2035.
• The shares underlying these options will vest upon the earlier of (i) June 17, 2026, or (ii) the date of the next Annual Meeting of Stockholders of Rapport Therapeutics, Inc.
• Vesting is contingent on Mr. Paul's continued service as a Director on the vesting date.
• Following this transaction, Mr. Paul beneficially owns 21,850 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options to a director aligns their interests with shareholders, which is generally viewed favorably. However, it's a routine compensation event and not indicative of significant operational news.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term company performance.
• This is a standard compensation practice for directors, indicating normal corporate governance procedures.

Future Outlook

The future outlook for the granted options is tied to the vesting conditions, which include continued service until June 17, 2026, or the date of the next Annual Meeting of Stockholders, whichever comes earlier. The options have a long-term expiration date of June 17, 2035.

Industry Context

This Form 4 filing represents a routine insider transaction, specifically an equity grant, which is a common practice in the biotechnology and pharmaceutical industry to compensate and incentivize directors and executives. Such grants are standard mechanisms for aligning the interests of company leadership with those of shareholders.

Comparison to Industry Standards

• The grant of stock options to a director is a standard form of equity compensation widely adopted across the biotech and pharmaceutical sectors.
• The vesting schedule, tied to continued service and specific dates or corporate events (Annual Meeting), is typical for director compensation plans, aiming to retain talent and ensure long-term commitment.
• The exercise price being set at the market price on the grant date (implied by the nature of a stock option grant) is a common industry practice.

Related Party Transactions

• The grant of stock options to Steven M. Paul, a Director of Rapport Therapeutics, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board. This is a standard and disclosed form of compensation.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial incentives with shareholder value creation, as the options gain value if the stock price increases.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• Vesting of the 21,850 stock options upon the earlier of June 17, 2026, or the date of the next Annual Meeting of Stockholders, subject to continued service.

Key Dates

Keywords

Rapport Therapeutics, RAPP, Stock Option Grant, Director Compensation, Insider Transaction, SEC Form 4, Equity Compensation, Corporate Governance